Nexthera Capital LP acquired a new stake in shares of Alkermes PLC (NASDAQ:ALKS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,400 shares of the company’s stock, valued at approximately $550,000.

Other large investors have also added to or reduced their stakes in the company. State Street Corp increased its stake in Alkermes PLC by 6.1% in the first quarter. State Street Corp now owns 3,974,002 shares of the company’s stock valued at $232,480,000 after buying an additional 228,719 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in shares of Alkermes PLC during the first quarter valued at $597,000. Marsico Capital Management LLC boosted its stake in shares of Alkermes PLC by 3.9% in the first quarter. Marsico Capital Management LLC now owns 63,398 shares of the company’s stock valued at $3,709,000 after buying an additional 2,400 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Alkermes PLC by 9.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 442,320 shares of the company’s stock valued at $25,876,000 after buying an additional 39,213 shares in the last quarter. Finally, KCG Holdings Inc. boosted its stake in shares of Alkermes PLC by 171.4% in the first quarter. KCG Holdings Inc. now owns 27,573 shares of the company’s stock valued at $1,613,000 after buying an additional 17,415 shares in the last quarter. 97.33% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Alkermes PLC (NASDAQ ALKS) traded down 1.92% on Thursday, hitting $58.33. 677,585 shares of the company traded hands. Alkermes PLC has a 1-year low of $39.65 and a 1-year high of $63.40. The firm’s 50 day moving average price is $58.56 and its 200 day moving average price is $57.16. The firm’s market capitalization is $8.94 billion.

Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.07. The business had revenue of $191.80 million for the quarter, compared to the consensus estimate of $195.79 million. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. The firm’s revenue for the quarter was up 22.3% compared to the same quarter last year. During the same period last year, the business posted ($0.16) EPS. Equities research analysts predict that Alkermes PLC will post ($0.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/06/15/9400-shares-in-alkermes-plc-alks-acquired-by-nexthera-capital-lp.html.

Several equities research analysts have recently weighed in on the company. Leerink Swann cut Alkermes PLC from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $68.00 to $61.00 in a research report on Tuesday. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. TheStreet upgraded Alkermes PLC from a “d+” rating to a “c” rating in a research report on Wednesday, February 15th. Morgan Stanley reiterated an “equal weight” rating and set a $62.00 price target on shares of Alkermes PLC in a research report on Monday, April 24th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $70.00 price target on shares of Alkermes PLC in a research report on Wednesday, June 7th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Alkermes PLC has an average rating of “Hold” and a consensus target price of $63.10.

In other Alkermes PLC news, insider Shane Cooke sold 1,900 shares of Alkermes PLC stock in a transaction that occurred on Tuesday, March 21st. The stock was sold at an average price of $60.09, for a total value of $114,171.00. Following the sale, the insider now owns 72,048 shares of the company’s stock, valued at approximately $4,329,364.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn L. Biberstein sold 15,000 shares of Alkermes PLC stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $57.68, for a total value of $865,200.00. Following the completion of the sale, the chief accounting officer now directly owns 69,904 shares in the company, valued at approximately $4,032,062.72. The disclosure for this sale can be found here. Insiders have sold a total of 174,800 shares of company stock worth $10,136,406 in the last three months. 5.34% of the stock is owned by corporate insiders.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.